BiotechTube

dirucotide

Phase 2/3Terminated
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Feb 1, 2007 → Sep 1, 2009

NCT ID
NCT00870155

About dirucotide

dirucotide is a phase 2/3 stage product being developed by Eli Lilly for Secondary Progressive Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00870155. Target conditions include Secondary Progressive Multiple Sclerosis.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00870155Phase 2/3Terminated

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
dirucotide + PlaceboEli LillyPhase 2/3
65
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Birabresib Dose 20 mgMerckPhase 1
33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
77
RanibizumabNovartisApproved
85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85